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Abstract
The inflammatory response following ischemic stroke is dominated by innate immune cells: resident microglia and blood-
derived macrophages. The ambivalent role of these cells in stroke outcome might be explained in part by the acquisition of
distinct functional phenotypes: classically (M1) and alternatively activated (M2) macrophages. To shed light on the crosstalk
between hypoxic neurons and macrophages, an in vitro model was set up in which bone marrow-derived macrophages
were co-cultured with hippocampal slices subjected to oxygen and glucose deprivation. The results showed that
macrophages provided potent protection against neuron cell loss through a paracrine mechanism, and that they expressed
M2-type alternative polarization. These findings raised the possibility of using bone marrow-derived M2 macrophages in
cellular therapy for stroke. Therefore, 2 million M2 macrophages (or vehicle) were intravenously administered during the
subacute stage of ischemia (D4) in a model of transient middle cerebral artery occlusion. Functional neuroscores and
magnetic resonance imaging endpoints (infarct volumes, blood-brain barrier integrity, phagocytic activity assessed by iron
oxide uptake) were longitudinally monitored for 2 weeks. This cell-based treatment did not significantly improve any
outcome measure compared with vehicle, suggesting that this strategy is not relevant to stroke therapy.
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Introduction
It is now acknowledged that inflammation plays a major
pathophysiological role in ischemic stroke [1]. The inflammatory
response is dominated by innate immune cells of myeloid lineage:
resident microglia and blood-derived macrophages. However, it
remains to be shown whether the impact of macrophages on the
outcome of brain ischemia is deleterious [2] or beneficial [3]. As
they penetrate tissue, they respond to microenvironmental signals,
acquiring distinct functional phenotypes: classically (M1) or
alternatively activated (M2) macrophages. This versatile plasticity
may at least partly explain their ambivalent impact under
pathological conditions. M2 macrophages are important in
resolving the inflammatory response and play a part in debris
scavenging, tissue remodeling, and angiogenesis [4]. They were
shown to support neurorepair in various models of central nervous
system lesion [5,6,7]. In permanent focal cerebral ischemia,
protective mechanisms induced by M2 activation have been
shown to come into play soon after injury (24–48 h) and to last at
least 7 days when neuron phagocytosis and debris removal are
prevalent [8]. In transient focal ischemia, M2-type genes were
found to be induced as of 1 to 3 days after injury, peaking at 3 to 5
days. The majority of M2-type genes began to decrease at 7 days
and returned to pre-injury levels by day 14 [9].
Elucidating the impact of blood-derived macrophages on
neuron viability after focal cerebral ischemia is of great interest,
as it may lead to new therapeutic strategies for stroke patients. This
is especially important given the current lack of treatment options
apart from thrombolysis, which benefits only a very small
proportion of patients. The first study objective was therefore to
investigate the influence of blood-derived macrophages on neuron
survival under ischemic conditions. The interplay between the 2
cell types was modeled by co-culturing bone marrow-derived
macrophages with organotypic hippocampal slice cultures (OHCs)
that had been subjected to oxygen-glucose deprivation (OGD).
The results showed that macrophages provided potent protection
against neuron cell loss, through a paracrine mechanism. What is
more, they expressed M2-type alternative polarization. These
findings raised the possibility of using bone marrow-derived M2
macrophages as a cell-based intervention (CBI) for stroke.
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Consequently, the second objective was to assess the effect of M2
macrophage administration in an in vivo model of transient focal
cerebral ischemia.
The lack of translational success observed in stroke neuropro-
tection trials conducted thus far has led the community to propose
frameworks intended to improve the quality of preclinical stroke
studies [10], in particular in the field of CBI [11]. In vivo
experiments were therefore conducted in compliance with these
guidelines, with non-invasive MRI follow-up.
Materials and Methods
Animals
Animal investigations conformed to the Guide for the Care and
Use of Laboratory Animals published by the European Union
(EEC Council Directive 86/609). Protocol approval was granted
by our University ethics review board (CeLyne: Comite´ d’Ethique
Lyonnais pour les Neurosciences Expe´rimentales).
Overall Protocols
In vitro study. OHCs were prepared as detailed hereafter
and cultured for 2 days before being subjected to OGD for 30 min
and then further cultured for 2 days under normoxic normogly-
cemic conditions, with or without bone marrow-derived macro-
phage co-culture; they were then examined by immunofluores-
cence.
In vivo study. The experimental design is shown in
Figure 1A, and the number of animals in Table 1. In brief,
surgery (transient middle cerebral artery occlusion (tMCAO) or
sham) was performed on day 0 (D0). All animals were then imaged
by MRI on D3. Exclusion criteria were based on this first MRI
session: 1) signs of subarachnoid or intracerebral hemorrhage, and
2) an ischemic lesion confined to the striatum without cortical
involvement. Animals included at D3 were randomly assigned to
one of two treatment groups: 2 million M2 macrophages or
control (vehicle). Treatments were administered intravenously
(1 ml over 5 minutes) at D4. All included animals were followed up
longitudinally for 2 weeks post-surgery. Therapeutic benefit was
evaluated before (baseline) and after treatment by sensorimotor
testing and monitoring the following MRI endpoints: lesion size
and brain swelling (T2-weighted imaging), blood-brain barrier
(BBB) integrity (T1-weighted imaging before and after injection of
DOTA-gadolinium) and phagocytic activity as neuroinflammation
marker (quantitative T2 values before and 24 h after injection of
ultrasmall particles of iron oxide (USPIO)). USPIO injections were
randomized so as also to constitute a control non-USPIO group.
Animals were sacrificed at D16 after the last behavioral
examination, and prepared for immunohistological analysis. All
examiners assessing MRI, behavior and histopathological data
were blinded to treatment allocation.
Organotypic Hippocampal Culture
Hippocampal slices were prepared from 7 day-old C57Bl6J
mice (Charles River, France) as previously described [12]. Briefly,
hippocampi were rapidly removed under sterile conditions, placed
into ice-cold medium and cut into transverse 200-mm slices using a
McIllwain tissue chopper. Slices were then cultured on semi-
permeable membrane inserts (Millipore, Bedford, MA, USA), in 6-
well culture plates containing 1 ml culture medium per well
(composition: 50% Dulbecco’s Modified Eagle Medium (DMEM)
(Invitrogen, Carlsbad, CA, USA), 25% normal horse serum, 25%
Hank’s Buffer Salt Solution, 1% L-glutamine, 1% penicillin-
streptomycin and 6.5 mg/ml glucose. OHCs were cultured for 2
days at 37uC in a 5% CO2-enriched atmosphere before OGD.
Oxygen-glucose Deprivation
Slices were washed 3 times in serum- and glucose-deprived
medium (75% basal medium essential, 25% Hank’s Buffer Salt
Solution, 1% L-glutamine) before being transferred to a hypoxic
chamber (95% N2, 5% CO2). Hypoxia was performed by
incubation in an air-tight humidified glass chamber (Verretech,
Lyon, France) at 37uC ventilated with N2 95%+CO2 5%.
OHCs were subjected to OGD for 30 min at 37uC and then
further cultured for 2 days in serum-free glucose-replete
medium (75% basal medium essential, 25% Hank’s Buffer Salt
Solution, 2% B27, 1% L-glutamin and 6.5 mg/ml glucose)
under normoxic conditions, as previously described [12]. As
appropriate, OHCs were co-cultured for 2 days with bone
marrow-derived macrophages after OGD. Bone marrow-derived
macrophages were cultured on the plastic surface of 6-well
plates, to prevent any physical contact with the hippocampal
slices cultured on permeable membrane inserts. Three indepen-
dent experiments were performed.
Primary Culture of Bone Marrow-derived Macrophages
Animals were sacrificed by intraperitoneal injection of pento-
barbital, and bone marrow cells were harvested by flushing out
tibias and femurs. Total bone marrow cells were then seeded on
uncoated 6-well plates at 56105 cells/ml in Iscove’s Modified
Dulbecco’s Medium (IMDM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 15% fetal calf serum (Fetal Clone II, Hyclone),
penicillin-streptomycin (1 mg/ml) and 10 ng/ml human macro-
phage-colony stimulating factor (hM-CSF) (PrepoTech Inc, Rocky
Hill, NJ, USA). Cultures were incubated at 37uC in a moist 5%
CO2-95% air. Seven days after plating, non-adherent cells were
harvested and adherent cells were washed twice in PBS.
As appropriate, bone marrow-derived macrophages were
stimulated with murine Interferon-c (50 ng/ml) (PrepoTech Inc,
Rocky Hill, NJ, USA) for 18 h or murine Interleukin-4 (50 ng/ml)
(PrepoTech Inc, Rocky Hill, NJ, USA) for 48 h, to generate M1
classically-activated macrophages or M2 alternatively-activated
macrophages respectively, as previously described [13,14]. Oth-
erwise, bone marrow-derived macrophages were not further
stimulated (M0 macrophages). Macrophage cell culture purity
under these experimental conditions was repeatedly found to
exceed 95% on immunocytofluorescence or FACS analysis of
CD11b+ cells (data not shown).
Immunohistofluorescence
Hippocampal slices were fixed with 4% paraformaldehyde for
10 min at room temperature. They were then rinsed 3 times in
PBS (Euromedex, Mundolsheim, France) and incubated for
30 min at room temperature with a blocking solution of 4%
bovine serum albumin (IDbio, Limoges, France) diluted in PBS
and supplemented with 10% normal goat serum (Vector
laboratories, Burlingame, CA, USA). They were then incubated
overnight at 4uC with mouse anti-mouse neuronal nuclei (NeuN)
antibody (Chemicon International, Temecula, CA, USA). Anti-
bodies were diluted 1:100 in blocking solution. Tissues were then
rinsed 3 times in PBS and incubated with a biotinylated goat anti-
mouse (Molecular Probes, Saint-Aubin, France) for 1 h at room
temperature. After 3 washes, they were finally incubated with
streptavidin-Alexafluor (488 or 506, Molecular probes, Saint-
Aubin, France) diluted 1:100 in PBS. 49, 6-Diamidine-2-
phenylindole dihydrochloride (DAPI, Roche, Mannheim, Ger-
many) nuclear staining was performed and the slides were
mounted using Fluoroprep (BioMerieux, Marcy l’Etoile, France).
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Immunohistofluorescence Image Analysis
To assess neuron cell loss in the hippocampal slices, the surface
covered by NeuN staining was measured in the dentate gyrus.
Images from selected areas were digitally photographed under
high magnification using a fluorescent microscope (Zeiss Axioplan
II) coupled to a CDD camera (F-View II; Soft Imaging System).
Image analysis was then performed using analySIS software
(analySIS 3.0; Soft Imaging System). A 0.04 mm2 region of interest
(ROI) was first defined and measured in the selected area. Then,
the area occupied by NeuN staining was determined by automatic
measurement of the area of pixels above a threshold value. Finally,
the NeuN immunostaining area was indexed to the total ROI
area, thereby estimating the density of NeuN staining. In each
experiment (n = 3), measures obtained in control OHCs were
attributed the arbitrary value of 100%, with all other measures
expressed as a percentage of this value.
mRNA Extraction and Reverse Transcription
mRNAs were extracted with the RNeasy Mini Kit (Qiagen,
Courtaboeuf, France) from macrophages that had been co-
cultured with OHCs, M0 macrophages (non-stimulated), M1
macrophages and M2 macrophages. Total RNA (20 ng) was then
reverse transcribed and cDNA amplified using the QuantiTect
Whole Transcriptome kit (Qiagen, Courtaboeuf, France).
Figure 1. Experimental protocol and diagram of MRI session. (A) Experimental protocol. Surgery consisted in either transient middle cerebral
artery occlusion (tMCAO) or sham operation. Treatment consisted in intravenous injection of either 2 million M2 macrophages diluted in 1 ml
phosphate-buffered saline (PBS) or the same volume of pure PBS. The number of animals included is given in Table 1. (B) Diagram of one MRI session.
T1/T2-WI: T1/T2-weighted imaging; MSME: Multi-Slice Multi-Echo; USPIO: ultrasmall superparamagnetic particles of iron oxide. BBB: blood-brain
barrier. The sequence parameters are given in Table 3.
doi:10.1371/journal.pone.0067063.g001
Table 1. Number of animals included.
Rats operated: 31 tMCAO: 24 tMCAO rats excluded based on D3 MRI: 8 Included in analysis*
tMCAO rats included:
16
M2-treated: 8 with USPIO: 5 8
without USPIO: 3
PBS-treated: 8 with USPIO: 5 8
without USPIO: 3
Sham: 7 Sham rats excluded based on D3 MRI: 0 Included in analysis*
Sham rats included: 7 M2-treated: 2 with USPIO: 2 2
PBS-treated: 5 with USPIO: 5 3 (2 animals excluded because of
incomplete data sets)
*Rats that had a complete set of longitudinal MRI data.
tMCAO: transient middle cerebral artery occlusion; PBS: Phosphate buffer saline; USPIO: Ultrasmall superparamagnetic particles of iron oxide.
doi:10.1371/journal.pone.0067063.t001
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Real-time Quantitative Reverse Transcription PCR (Q-
RTPCR)
Synthesized cDNA was measured on Q-RTPCR (SYBR Green
PCR, LightCycler, Roche Diagnostics, Indianapolis, IN, USA)
following the manufacturer’s recommendations. The LightCycler
experimental protocol consisted of an initial Taq activation at
95uC for 8 minutes followed by a touchdown PCR step of 12
cycles consisting of 15 s at 95uC, 5 s at 68uC and 8 s at 72uC,
followed by 33 cycles consisting of 15 s at 95uC, 5 s at 60uC, and
10 s at 72uC, with a single fluorescence measurement. Primers
were designed with Primer3 software (Whitehead Institute/MIT,
MA, USA) and purchased from Eurogentec (Seraing, Belgium).
The following primers were used: Arginase 1, IL-6, inductible
nitric oxide synthase (NOS2) and TNF-a. They are described in
details in Table 2. All primers had Tms between 59uC and 61uC
and all products were 100–200 bp. Cyclophilin A mRNA was
used as internal standard to control amplification variation due to
differences in baseline mRNA concentration. Relative mRNA
levels for each tissue were computed from the threshold cycle (Ct)
values obtained for the target gene, the efficiency of the primer set,
and cyclophilin mRNA levels in mouse samples using RealQuant
software (Roche Diagnostics, GmbH, Mannheim, Germany;
version 1.01). Two independent experiments of RT-PCR were
performed. Both series analyzed genes expression in M0, M1, M2
macrophages and bone marrow-derived macrophages cultured in
the presence of oxygen/glucose-deprived OHCs, allowing com-
parison between macrophages activation programs. Only the first
series additionally comprised bone marrow-derived macrophages
cultured in the presence of control OHCs.
Induction of Transient Focal Cerebral Ischemia by Middle
Cerebral Artery Occlusion
Adult male Sprague–Dawley rats (Centre d’Elevage Rene´
Janvier, France; 280 g body weight) were used. The intraluminal
suture model was performed as previously described by Longa
et al. [15]. Briefly, the rats were anesthetized and maintained by
1.0% isoflurane in air using a face mask. Rectal temperature was
kept at 37u61uC throughout the surgical procedure, using a
feedback-regulated heating pad. After temporary ipsilateral
common carotid artery (CCA) clamping, tMCAO was induced
by advancing a filament (0.37 mm diameter, Doccol Corporation,
Redlands, CA, USA) from the external carotid artery into the
lumen of internal carotid artery to block the origin of the right
MCA. The CCA clamp was then removed during occlusion. After
1 hour, the endovascular suture was withdrawn into the stump of
the external carotid artery to allow reperfusion. For the sham
group, the filament was inserted without being advanced to the
MCA bifurcation. To alleviate pain, animals received 0.05 mg/kg
subcutaneous buprenorphine (Temge´sic, Schering-Plough Canada
Inc., Kirkland, QC, Canada) immediately after induction of
anesthesia.
Behavioral Examination
Rats were familiarized with the test environment (quiet room,
low light). Each session consisted in evaluation of functional
recovery on 2 behavioral tests [16].
Modified Neurological Severity Score: The modified Neurological
Severity Score (mNSS) is a composite of motor, sensory and
balance tests. Neurologic function was graded on a scale of 0 to 14:
the higher the score, the more severe the injury.
Adhesive-removal somatosensory test: Two small adhesive-backed
paper dots (1 cm2) were used as bilateral tactile stimuli occupying
the distal–radial region on the wrist of each forelimb. The rat was
then returned to its home-cage. The time to remove each stimulus
was recorded for 3 trials per day. Individual trials were separated
by at least 5 mins. The animals had been pre-trained for 3 days
before surgery.
MR Imaging
MRI was performed on a Bruker Biospec 7T/12-cm magnet,
interfaced to a Paravision 5.0 device (PV5.0, Bruker, Ettlingen,
Germany), using a birdcage head-coil of 72 mm inner diameter
for transmission and a 25 mm diameter surface coil for reception.
The animal was placed in a non-magnetic holder equipped with a
nose cone for administration of anesthetic gas (1.5% isoflurane),
stereotaxic ear bars, an integrated water-heating system to
maintain body temperature at 37u61uC, and a pressure probe
to monitor respiration. The MR imaging session is depicted in
Figure 1B and sequences are described in Table 3.
Contrast Agents
DOTA-gadolinium (DotaremH, Guerbet, Aulnay-sous-Bois,
France) was administered via an intravenous catheter in the
caudal vein, at a dose of 0.4 mmol/kg.
P904 USPIOs (Guerbet Research, Aulnay-sous-Bois, France)
were administered via the same route at a dose of 1 mmol Fe/kg.
This contrast agent is composed of an 8-nm crystalline iron oxide
core (maghemite c-Fe2O3) coated with a hydrophilic material for
stabilization and biocompatibility. Its mean hydrodynamic diam-
eter is 25 nm (range: 20 to 50 nm). P904 r1 relaxivity is
1.660.2 mM21s21 at 7 T in 4% HAS (a medium close to plasma)
at 37uC, and r2 relaxivity is 9465 mM21s21 under the same
conditions.
MR Image Analysis
Data were processed using in-house software developed at
Grenoble Institute of Neuroscience in the Matlab environment
(MathWorks, Natick, MA, USA) [17]. Lesion, ipsilateral hemi-
Table 2. Primers used in PCR reactions.
Transcript Accession number Sense primer Antisense primer Product size (bp)
Arg1 NM_007482 TCACCTGAGCTTTGATGTCG TTCCCAAGAGTTGGGTTCAC 171
Il6 NM_031168 CTGACAATATGAATGTTGGG TCCAAGAAACCATCTGGCTAGG 159
Nos2 NM_010927 AAGCTGAACTTGAGCGAGGA TGCCCATAGGAAAAGACTG 105
Tnf NM_013693 CTTGTTGCCTCCTCTTTTGC AATGACCCGTAGGGCGATTA 151
CypA NM_008907 ATGGCAAATGCTGGACCAAA GCCTTCTTTCACCTTCCCAAA 108
Arg1: arginase; Il6: interleukin 6; Nos: 2 nitric oxide synthase2 inducible; Tnf: tumor necrosis factor; CypA: Cyclophilin A.
doi:10.1371/journal.pone.0067063.t002
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sphere (IH) and contralateral hemisphere (CH) were manually
delineated on T2-weighted imaging. The IH:CH ratio was used to
evaluate brain swelling. Infarct areas were corrected for brain
swelling by dividing them by the IH:CH ratio, and infarct volumes
were then calculated by integrating the resulting corrected areas
over all slices, taking slice thickness into account.
T2 maps were generated by monoexponential fitting of the
native data using a Levenberg–Marquardt algorithm. Because
hypointense signals related to USPIO uptake were only observed
in perilesional areas, 3.3 mm2 ROIs were systematically placed on
the T2 maps in the perilesional striatum and corresponding
contralateral region. Drop in T2 in the ipsilateral compared to the
contralateral hemisphere was assessed as:
% T2= [T2(ipsilateral) - T2(contralateral)]/T2(contralateral).
Tissue Preparation and Histology
Brains were dissected, frozen at 280uC and cut into 16 mm
sections by cryostat. The sections were fixed in 4% paraformal-
dehyde for 15 min at room temperature. After 30 min endoge-
nous peroxidase blocking, slices were washed with 0.1% PBS-
Tween and incubated overnight at 4uC in PBS/3% BSA with
monoclonal mouse anti–ED1 (AbC117-6714, 1:1000; AbCys,
Paris, France), an antibody directed against the CD68 membrane
receptor present on rat macrophage lysosomal membranes.
Sections were then rinsed with 0.1% PBS-Tween and incubated
with biotinylated horse anti-mouse secondary antibody for 1 h at
room temperature (1:500; Vector Laboratories, Burlingame, CA,
USA). Sections were then treated with extravidin-peroxidase for
1 h at room temperature (1:1000; Sigma-Aldrich, St. Louis, MO,
USA) followed by 0.2 mg/ml diaminobenzidine in 50 mmol/L
pH 7.6 Tris-HCL buffer in PBS with 0.01% hydrogen peroxide
until stained. Finally, sections were counterstained with nuclear
red.
Immunohistology Image Analysis
Entire brain sections were captured with a digital camera (F-
View II; Soft Imaging System) using the 106 magnification
microscope lens (Zeiss Axioplan II) and analyzed on ImageJ
software (ImageJ 1.41, NIH, MD, USA). An ROI was first defined
so as to encounter both lesional and perilesional areas. Then, the
area occupied by ED1 staining was determined by automatically
measuring the area of pixels above a threshold value. Finally, the
area of ED1 immunostaining was indexed to the total ROI area,
so as to estimate ED1 staining density. In addition, the number of
ED1-immunopositive (ED1+) cells was counted manually in a 0.11
mm2 ROI within the perilesional area (same location as for MRI
measurements).
Statistical Analysis
Statistical analysis was performed with the SPSS 17 (SPSS
Science) statistical software package for Windows. Data are given
as mean 6 standard deviation. Longitudinal data were assessed by
analysis of variance for repeated measures using the general linear
model, followed by post-hoc Bonferroni test. The number of
animals in each group was based on power analysis assuming a
standard deviation of 25% and a treatment effect of 30%. Animals
without a complete set of data for the 2 weeks were excluded from
analysis. Non-parametric Mann-Whitney tests were used for
single-point comparison. Pearson correlation coefficients were
calculated to assess the relationship between MRI and immuno-
histological endpoints. Chi-square tests were used to assess the
difference between the proportions of animals with or without
prolonged BBB disruption. Probability values of 0.05 or less were
considered to indicate statistical significance.
Results
Macrophages Prevent Hypoxia-induced Neuron Cell
Death in vitro
In OHCs subjected to OGD, neuron cell loss could be
demonstrated in different hippocampal neuron populations
(dentate gyrus granular cells and pyramidal cells of Ammon’s
horn), as assessed by NeuN staining (Figure 2 A–D) or DAPI
coloration (data not shown). While the extent of neuron cell loss
varied from one experiment to another, dentate gyrus granular
neurons were systematically affected by OGD (Figure 2B, 2D).
Macrophage co-culture had a striking protective effect on oxygen-
glucose deprived hippocampal neurons (Figure 2E–F): compared
to control OHCs, neuron survival was 35% 68% in hypoxic slices
and 70%610% in hypoxic slices co-cultured with macrophages
(Figure 2G). This represents an increase of nearly 100% in neuron
survival under bone marrow-derived macrophage co-culture.
Hippocampal Slices Subjected to Hypoxia Trigger an
Alternative Activation Program in Macrophages
The cytokine profile of the macrophage co-cultures was then
assessed at the mRNA level by Q-RTPCR examination of
transcripts coding M1-type cytokines (TNF-a, IL-6, iNOS) or
Arginase 1, a molecule expressed by alternatively-activated
macrophages (Figure 3). In two independent experiments,
Table 3. MR imaging parameters.
Imaging Parameters
Spin-echo RARE T2-weighted
images
Gradient-echo FLASH T1-weighted
images
Multi-slice multi-echo (MSME) for T2
maps
TE/TR (ms/ms) 75/3,000 3.6/161.7 11.7/4,000
Flip angle (degrees) 180 90 90
No. of signals acquired 2 2 8 echoes, inter-echo delay: 23.3 ms
Bandwidth (kHz) 50 101 303
Field of view (mm2) 40640 40640 40640
Slice thickness/Gap (mm) 1.5/0.5 1/0 1.5/0.5
Number of slices 7 15 7
Matrix size 2566256 2566256 256692
TE = echo time; TR = repetition time.
doi:10.1371/journal.pone.0067063.t003
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Figure 2. Co-cultured macrophages prevent hypoxia-induced neuronal cell death in vitro. A–F: NeuN staining was performed on control
organotypic hippocampal cultures (control OHCs), OHCs subjected to oxygen-glucose deprivation (OGD) (hypoxia) or OHCs subjected to OGD and
co-cultured with macrophages (hypoxia+macrophages). Low magnification views of hippocampal slices are shown in A, C and E. High magnification
views of the dentate gyrus are shown in B, D and F. As compared to control hippocampal slices (A, B), neuron cell loss was demonstrated in oxygen/
glucose-deprived OHCs (C, D) and was found to affect the dentate gyrus systematically. In contrast, oxygen/glucose-deprived OHCs that were co-
cultured with macrophages appeared partially protected from OGD-induced neuron cell death. G: A quantitative analysis of neuron density was
performed in the dentate gyrus by measuring the area covered by NeuN staining relative to the area analyzed. An arbitrary value of 100% was
attributed to the measures obtained in control OHCs. Data showed a mean 35%68% neuron density relative to controls in oxygen/glucose-deprived
OHCs (hypoxia) and that co-culture with macrophages (hypoxia+macrophages) allowed neuron density to reach 70% 610% relative to controls
(Mann-Whitney, n = 3 experiments in each group, ***: p,0.001).
doi:10.1371/journal.pone.0067063.g002
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macrophages co-cultured with hypoxic brain slices, did not show
increased expression of M1-type genes as compared to unstimu-
lated macrophages (referred to as M0) or M2 macrophages
(obtained by IL-4 stimulation of bone-marrow derived macro-
phages). On the contrary, as compared to M0 or M1
macrophages, increased expression of Arginase-1 was observed
in both macrophages co-cultured with OGD brain slices and M2
macrophages. Overall, these results indicate that macrophages co-
cultured with OGD brain slices tend to express a M2-type
alternative phenotype and did not engage a M1 activation
program.
M2 Macrophages Do Not Protect against Ischemic
Damage in vivo
To assess the relevance of these in vitro findings to stroke
therapy, M2 macrophages were administered in a model of focal
cerebral ischemia. Table 1 summarizes the number of animals
included in the study and analyzed: 8 animals were excluded at D3
because of a small, striatal-restricted, infarct; 2 animals did not
have a complete set of longitudinal MRI data because of technical
problems (10 animals excluded in total). Intravenous administra-
tion of 26106 M2 macrophages 4 days after reperfusion did not
significantly improve functional outcome, assessed longitudinally
for 2 weeks post-tMCAO with either of the behavioral tests
(mNSS: p= 0.505; adhesive tape removal test: p = 0.699) (Figure 4).
Figure 5A shows the cortico-striatal lesion of 1 representative
tMCAO animal at D3, D7 and D14, detected by hyperintense
signal on T2-weighted images (with pseudo-normalization, the so
called ‘‘fogging effect’’, at D7 and D14). There was no statistically
significant difference in brain swelling (p = 0.941, Figure 5B) or
lesion volume (p= 0.346, Figure 5C) between treated and vehicle
groups. To assess BBB integrity, T1-weighted images were
acquired before and after intravenous administration of DOTA-
gadolinium. Extravasation was observed in the whole lesion at D3
in all tMCAO animals. Prolonged BBB disruption, demonstrated
by sustained T1 enhancement after D3, was observed in 41% (7/
17) of tMCAO animals, but appeared to be independent of
treatment, as the same proportion was found in the treated (3/8,
38%) and vehicle (4/9, 44%) groups (chi-squared test, p = 0.7).
To assess neuroinflammation, T2 maps were acquired before
and 24h after intravenous USPIO administration. USPIOs are
engulfed in vivo by phagocytic cells, which thus become detectable
on MRI [18]. A diffuse weak drop in T2 signal was seen in the
perilesional area in tMCAO+USPIO animals at all time-points
post-injection, regardless of the spatio-temporal pattern of BBB
disruption (Figure 6A, arrow). Analyzing data quantitatively,
Figure 3. Hypoxic hippocampal slices trigger an alternatively-activated program in macrophages. Bone marrow-derived macrophages
were cultured in the presence of control (Control) or oxygen/glucose-deprived OHCs (Hypoxia) in 6-well culture plates. Macrophages from each
experimental condition were pooled and assessed by Q-RTPCR for the expression of the following genes: inductible nitric oxide synthase (iNOS), IL-6,
TNF-a and Arginase-1. As controls, analyses were performed in parallel on mRNAs extracted from M1 macrophages (stimulated with IFN-c), M2
macrophages (stimulated with IL-4) or M0 macrophages (non-stimulated). Data showed that, as expected, iNOS and the pro-inflammatory cytokines
IL-6 and TNF-a were highly expressed in M1 macrophages as compared to M0 or M2 macrophages. With regard to these M1-type pro-inflammatory
genes, bone marrow-derived macrophages co-cultured with oxygen/glucose-deprived OHCs (Hypoxia) exhibited low levels of mRNA expression and
a similar profile to bone marrow-derived macrophages co-cultured with control OHCs (Control). In contrast, the M2-type gene Arginase-1 was highly
expressed in hypoxic macrophages (co-cultured with oxygen/glucose-deprived OHCs) as compared to control macrophages (co-cultured with control
OHCs). As expected, Arginase-1 was also highly expressed in M2 macrophages as compared to M0 or M1 macrophages. Data shown are
representative of two independent experiments.
doi:10.1371/journal.pone.0067063.g003
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independently of treatment group, the percentage T2 difference
between ipsilateral and contralateral hemispheres was significantly
smaller in the (tMCAO with USPIO) group than in the (tMCAO
without USPIO) (ANOVA for repeated measures, p = 0.001) or
(sham with USPIO) group (Figure 6C, p= 0.004). These results
suggested that the T2 signal drop reflected iron accumulation
specifically related to tMCAO, rather than a fogging phenomenon
due to clearing processes [19]. This was consistent with abundant
ED-1+ cells detected in the perilesional area of all tMCAO
animals on immunohistology (Figure 6B, arrow). Moreover,
quantitative analysis of ED1 immunostained slices revealed a
significant correlation between stained area and %T2 (R2= 0.803,
p = 0.009). No significant effect of M2 treatment on %T2 was
found in (tMCAO with USPIO) animals at any time point
(ANOVA for repeated measures, p = 0.523). In line with this
finding, there was no significant difference in the number of ED1+
cells between M2-treated (1586106) and control animals
(1866105) (p = 0.705, Mann-Whitney test).
Discussion
In the last decade, the concept of macrophage activation
programs has shed new light on the roles exerted by the
mononuclear phagocyte system under diverse pathologic condi-
tions [13,14,20]. Beside the classical activation program (known as
the M1 program), which can be induced by lipoplysaccharide
(LPS) or interferon-c (IFN-c), macrophages may engage different
types of alternative activation programs (known as M2 programs)
that were shown to favor tissue repair, to dampen acute
inflammation or, in the case of tumor-infiltrating macrophages,
to support tumor outgrowth [13,14,20]. Signals that trigger such
alternative activation programs are likely delivered in the local
Figure 4. M2 macrophages do not improve functional outcome after ischemic stroke. A- mNSS test. B- Adhesive removal test. There was
no statistical difference in rat performance before treatment (D2) for either behavioral test. After treatment (D11 and D16), there was an improvement
in neuroscores in both treatment groups, but no statistically significant difference between them (analysis of variance for repeated measures, N = 8 in
each group, p = 0.505). Similarly, time to remove the adhesive was slightly improved in both groups, without any significant difference (analysis of
variance for repeated measures, N = 8 in each group, p = 0.699). PBS: phosphate-buffered saline (used as vehicle for cell delivery).
doi:10.1371/journal.pone.0067063.g004
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environment of blood-derived macrophages and notably include
IL-4 and IL-10.
In the present experimental setting, hippocampal slices subject-
ed to hypoxia released soluble factors that triggered an M2-type
activation program in co-cultured bone marrow-derived macro-
phages. In this regard, it is noteworthy that insulin growth factor-1
(IGF-1), a cytokine known to be synthesized by M2 macrophages,
was previously shown to prevent ischemia-induced neuron cell
Figure 5. M2 macrophages do not reduce lesion size after ischemic stroke. A- Typical T2-weighted images obtained at D3, D7 and D14
post-ischemia showing the lesion as a hyperintense signal. B- The ratio of hemisphere volumes [ipsilateral:contralateral] showed moderate brain
swelling at D3, normalization at D7 and moderate atrophy at D14. No statistically significant difference was seen between treatment groups (analysis
of variance for repeated measures, N = 8 in each group, p = 0.941). C- Before treatment (D3), lesion volume (corrected for brain swelling/atrophy) was
not significantly different between groups. Likewise, after treatment (D7 and D14), there was no significant difference between groups (analysis of
variance for repeated measures, N = 8 in each group, p = 0.346).
doi:10.1371/journal.pone.0067063.g005
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death [21,22]. With regard to the overall neuroprotective effects of
M2 macrophages, the present results are in line with previous
reports that infiltrating blood-derived macrophages expressed an
M2 phenotype and supported tissue repair in a model of spinal
cord injury [6] and in a model of multiple sclerosis [23]. However,
to our knowledge, the present study is the first to demonstrate the
effectiveness of M2 macrophages in protecting neurons subjected
to ischemia. This effect, mediated by soluble factors, appears
similar to the neuroprotection provided by bone marrow
mesenchymal stem cells (BMSCs) on oxygen/glucose-deprived
OHCs [24]. This suggests that BMSCs and M2 macrophages may
support survival of hypoxic neurons through common paracrine
mechanisms.
Overall, the first experiment showed that M2 activated
macrophages can exert neuroprotective effects under ischemic
conditions. This led us to investigate the potential of using M2
macrophages in cellular therapy in focal cerebral ischemia. CBI
has been emerging as a new promising modality for treating stroke
since the 1990 s. Various types of cellular preparation, mainly
involving stem cells, have been shown to improve functional
outcome in experimental stroke [25]. To our knowledge, the
present study is the first to assess M2 macrophages as CBI
candidates. The results were disappointing, with no improvement
in outcome, whether functional or lesional. This failure of
translation from an in vitro to an in vivo model might be explained
in part by delayed in vivo injection. In most studies reporting
benefit, cells were administered during the acute phase of
Figure 6. M2 macrophages do not reduce cerebral USPIO uptake after ischemic stroke. A- Typical T2-weighted images obtained before
and 24 h after intravenous USPIO injection. The arrow shows the slight hyposignal detected in the perilesional area. B- Abundant ED-1+ cells were
detected at the same location (arrow). C- Quantification of T2 difference between ipsilateral and contralateral hemisphere (%T2) showed that the T2
drop in the perilesional area was specific to tMCAO rats injected with USPIO (analysis of variance for repeated measures, *p,0.01). However, no effect
of M2 treatment on T2 changes was found (analysis of variance for repeated measures, N = 5 in each group, p = 0.523).
doi:10.1371/journal.pone.0067063.g006
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ischemia. Our rationale for injecting M2 macrophages during the
subacute stage was twofold. Firstly, this time-window seemed more
appropriate from a translational perspective, as production of M2
macrophages requires time. Secondly, this time-window corre-
sponded to a plateau for the recruitment of blood-derived
macrophages [26]. This led us to assume that the microenviron-
ment (cytokines, chemokines and adhesion molecules) would be
optimal for macrophage migration into the brain parenchyma.
However, bone marrow-derived M2 activated macrophages might
lack receptors to enter the brain, such as the chemokine receptor
CCR2 [27]. This could explain in part the lack of benefit, as the
CCR2-dependent recruitment of inflammatory monocytes and
their subsequent differentiation within the lesioned brain environ-
ment into noninflammatory phagocytes has been recently shown
to be a key mechanism linking postischemic brain inflammation
with repair [3].
On the other hand, immunomodulatory cells may not need to
enter the brain to elicit an effect, but may act in the periphery to
increase trophic factor expression in the brain [28]. This idea is
supported by the fact that the neuroprotective effect observed in
co-cultures of oxygen/glucose deprived OHCs with macrophages
was obviously mediated by secretion of protective soluble factors
without a need for direct cell-to-cell contact. The present results
may thus also be explained in part by dilution and/or insufficient
release of these factors after intravenous injection – a delivery
route chosen as being minimally invasive. Alternatively, endovas-
cular drug delivery could be performed by interventional
physicians and is potentially more comfortable for patients than
an intracranial route. However, a potential danger of this
approach is that cells might aggregate during the process of
injection, forming microemboli. In fact, our team has previously
shown that intra-carotid infusion of bone marrow-derived
macrophages increased mortality and induced brain lesions in a
tMCAO model [29].
Limitations
The issues remaining to be solved before moving on to clinical
applications of cell therapy in ischemic stroke have been recently
discussed and constitute the road map for the STEPS consortium
[11]. The present study had several limitations in the light of these
recommendations. Firstly, additional in vitro studies would be
needed to identify macrophage-derived factors that support
neuronal protection and neuronally-derived molecules that trigger
macrophage activation. It would also be of interest to determine
whether or not M1 activated macrophages afford a similar
protection to hypoxic neurons. Secondly, we did not perform any
in vivo dose-response study. The in vivo cell dose tested was,
however, based on a study by Mikita et al. [23], reporting
therapeutic benefit with M2 activated macrophages in a model of
multiple sclerosis, and was consistent with the cell dose chosen in
most studies of cellular therapy using intravascular administration.
Of note, however, in the study performed by Mikita and coll [23],
M2 macrophages were administered twice with a delay of 2 days
to induce a strong clinical and histological benefit. The
experimental design of the current study would allow such a
second M2 administration at D6. Additional experiments are thus
needed to completely explore the therapeutic potential of M2
macrophages beyond the single dose trial. Also, other ways of
administration (intra-cerebral, intra-arterial) might prove more
efficient despite their invasiveness. Thirdly, animal follow-up was
limited to 2 weeks, whereas longer term follow-up (up to one
month) is usually recommended. Nonetheless, the fact that no
endpoint differed between groups during this 2-week time-span
does not offer much hope for any subsequent improvement.
Finally, we did not study cell trafficking and final fate following i.v.
injection. Many macrophages might get trapped in other organs
such as the lungs and the liver. A non-invasive modality such as
MRI could monitor the delivery and tracking of exogenously
administered cells; however, as mentioned above, cells were not
especially expected to migrate into the brain, and the sensitivity of
MRI might be too low to detect small amounts of cells in the brain
parenchyma.
Conclusion
In conclusion, the present study failed to demonstrate a
protective effect of M2 macrophages administered intravenously
in the subacute stage of transient focal cerebral ischemia, despite
their neuroprotective effects observed in vitro. Immunomodulatory
therapy, such as M2 macrophage supplementation in peripheral
blood, has to take into account the complexity and dynamics of
both post-ischemic cerebral inflammation and post-ischemic
blood-brain barrier alterations.
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